Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

82.26EUR
18 Aug 2017
Change (% chg)

€-0.50 (-0.60%)
Prev Close
€82.76
Open
€82.01
Day's High
€82.56
Day's Low
€81.44
Volume
2,335,356
Avg. Vol
2,441,174
52-wk High
€92.97
52-wk Low
€66.72

Latest Key Developments (Source: Significant Developments)

Emergent Biosolutions updates terms of termination of agreement related to acquisition of Sanofi's acam2000 business
Friday, 14 Jul 2017 07:28am EDT 

July 14 (Reuters) - Emergent Biosolutions Inc ::Emergent Biosolutions updates on terms of any termination of agreement related to acquisition of acam2000 business from Sanofi.Emergent Biosolutions - agreement will become void and have no effect, except that certain specified obligations of Emergent and Sanofi shall survive.Emergent Biosolutions - certain specified obligations of both parties shall survive including those concerning confidentiality and public announcements.  Full Article

Emergent BioSolutions to acquire ACAM2000 business from Sanofi
Friday, 14 Jul 2017 07:00am EDT 

July 14 (Reuters) - Emergent Biosolutions Inc :Emergent biosolutions to acquire acam2000® business from sanofi.Emergent biosolutions to acquire acam2000® business from sanofi.Emergent biosolutions inc - deal for ‍all-cash consideration of $97.5 million upfront​.Emergent biosolutions inc - deal for all-cash transaction with a total value of up to $125 million.Emergent biosolutions-deal includes ‍all-cash consideration of $97.5 million upfront ​.Emergent biosolutions-deal also includes up to $27.5 million in near-term contingent regulatory & manufacturing-related milestones​.Emergent - deal expected to be accretive beginning with anticipated product deliveries in 2018 following fda licensure of u.s.-based manufacturing facility​.Emergent biosolutions-‍emergent will assume responsibility for existing 10-year cdc contract, which will expire and be up for renewal or extension in 2018​.Emergent biosolutions inc- intends to negotiate a follow-on, multi-year contract with u.s. Government to ensure continued supply of acam2000 to sns​.Emergent - ‍upon closing, co will assume all responsibilities under cdc contract valued at up to approximately $160 million​.Emergent biosolutions inc - anticipates product deliveries will resume in 2018, following expected fda licensure of u.s.-based manufacturing facility​.Emergent biosolutions - ‍expect deal to "meaningfully" contribute to revenue growth in 2018 & advance efforts towards achieving $1 billion in revenue by 2020​.  Full Article

Alnylam Pharmaceuticals and Sanofi Genzyme report positive results from ongoing phase 2 open-label extension study
Monday, 10 Jul 2017 09:30am EDT 

July 10 (Reuters) - Alnylam Pharmaceuticals Inc :Alnylam and Sanofi Genzyme report positive results from ongoing phase 2 open-label extension study with investigational RNAI therapeutic Fitusiran in patients with hemophilia A and B with or without inhibitors.Says majority of adverse events were mild/moderate in severity, with most common ae's consisting transient, mild injection site reactions.Says with up to 20 months of dosing, fitusiran safety and tolerability profile remains encouraging in the study.Says there was one discontinuation in study due to AE, an asymptomatic alanine aminotransferase elevation in patient with hcv infection.Says expect initial results of atlas phase 3 program in mid-to-late 2019.  Full Article

Lexicon Pharmaceuticals amends collaboration and license agreement
Friday, 7 Jul 2017 09:34am EDT 

July 7 (Reuters) - Lexicon Pharmaceuticals Inc ::Lexicon Pharmaceuticals - on july 1, 2017, entered into an amendment to collaboration and license agreement with Sanofi-Aventis Deutschland GMBH.Lexicon Pharmaceuticals Inc - remain eligible to receive an aggregate of $210 million upon achievement of amended clinical development milestones.Lexicon Pharmaceuticals - remain eligible to receive up to $220 million upon achievement of specified regulatory milestones.Lexicon Pharmaceuticals - remain eligible to receive up to $990 million upon the achievement of specified commercial milestones.Lexicon Pharmaceuticals - under amended milestones, eligible to receive up to $110 million upon achievement of 4 milestones.Lexicon Pharma-pursuant to amendment, co eligible to $100 million upon achievement of milestone based on results of studies in type 2 diabetes patients.  Full Article

Alnylam and Sanofi Genzyme initiate ATLAS Phase 3 program with investigational RNAi therapeutic fitusiran
Friday, 7 Jul 2017 07:30am EDT 

July 7 (Reuters) - Alnylam Pharmaceuticals Inc :Alnylam and Sanofi Genzyme initiate ATLAS phase 3 program with investigational RNAi therapeutic fitusiran.Says expect top-line data from the ATLAS trials in mid-to-late 2019.says ATLAS studies are expected to enroll about 250 patients across 3 separate trials conducted around the world.Says ATLAS to evaluate safety and efficacy of Fitusiran across broad spectrum of patients living with hemophilia.  Full Article

Rosa & Co announces renewal of multi-yr research agreement with Sanofi
Tuesday, 20 Jun 2017 06:12am EDT 

June 20 (Reuters) - Sanofi SA ::Rosa & Co announces renewal of multi-year research agreement with Sanofi.Rosa & Co says renewal of a multi-year research agreement with Sanofi to provide Rosa's PhysioPD services.  Full Article

Immunogen and Sanofi amend license agreements
Tuesday, 30 May 2017 08:30am EDT 

May 30 (Reuters) - Immunogen Inc :Immunogen and Sanofi amend license agreements.Immunogen - co, affiliate of Sanofi have amended their license agreements covering all compounds in development by sanofi using Immunogen's technology.Immunogen Inc - as consideration for these amendments, Immunogen will receive a $30 million payment.Immunogen - as consideration for amendments immunogen agreed to forego limited co-promotion option in U.S. With respect to compounds covered by 2003 agreement.Immunogen - as consideration for amendments immunogen has also agreed to forego future milestones or royalties under both license agreements.Immunogen Inc - also amended to grant Sanofi fully-paid, exclusive license to develop, manufacture, commercialize experimental compound SAR428926.  Full Article

Regeneron, Sanofi RA drug wins FDA nod; co's price it at $39,000/patient/yr
Monday, 22 May 2017 05:45pm EDT 

May 22 (Reuters) - Sanofi Sa :Regeneron and sanofi announce fda approval of kevzara® (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients.Regeneron pharmaceuticals inc - in u.s., kevzara will be marketed by regeneron and sanofi genzyme, specialty care global business unit of sanofi.Regeneron pharmaceuticals, inc says in clinical trial program, sarilumab was statistically significant.Regeneron - final decision on marketing authorization application for kevzara in european union will be made by european commission in coming months.Regeneron pharmaceuticals inc - u.s. Wholesale acquisition cost of kevzara is $39,000/year for 200 mg and 150 mg doses.  Full Article

Sanofi receives CHMP recommendation for approval of insulin lispro biosimilar
Friday, 19 May 2017 07:09am EDT 

May 19 (Reuters) - SANOFI SA :REG-SANOFI RECEIVES CHMP RECOMMENDATION FOR APPROVAL OF INSULIN LISPRO BIOSIMILAR.POSITIVE OPINION BASED ON A CLINICAL DEVELOPMENT PROGRAM INVOLVING OVER 1,000 PEOPLE WITH TYPE 1 OR TYPE 2 DIABETES.EUROPEAN COMMISSION IS EXPECTED TO MAKE A FINAL DECISION ON MARKETING AUTHORIZATION FOR INSULIN LISPRO SANOFI(® )IN COMING MONTHS.  Full Article

Frontier IP announces 250 mln euro licence option agreement with Sanofi
Tuesday, 9 May 2017 06:50am EDT 

May 9 (Reuters) - Frontier IP Group Plc ::Exscientia announces 250 mln euro collaboration for a multiple-product development and licence option agreement with Sanofi.  Full Article

BRIEF-Paulson & Co cuts share stake in Teva Pharmaceutical, Sanofi

* Paulson & Co Inc cuts share stake in Teva Pharmaceutical Industries Ltd by 38.7 percent to 6.7 million sponsored ADR - SEC filing